Recent News

• 04.01.2025 - Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
• 03.26.2025 - Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
• 03.24.2025 - Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
• 03.19.2025 - Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
• 03.12.2025 - Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
• 03.05.2025 - Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
• 03.04.2025 - Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
• 01.23.2025 - Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

Recent Filings

• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2025 - EX-99.1 EX-99.1
• 03.26.2025 - 8-K Current report
• 03.24.2025 - 8-K Current report
• 03.24.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.24.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2025 - 8-K Current report